药械

订阅

MedSci主页 / 所有栏目 / 药械

Pharmacotherapy：普拉德-威利综合症患者使用抗精神病药物和体重之间的关系

2015-03-31 范伟译 MedSci原创

普拉德-威利综合症
关注

背景:患有普拉德-威利综合征(PWS)的病人发展为行为和精神疾病的风险增加,常常需要抗精神病药物(APs)治疗。在一般人群中观察到抗精神病药物与体重增加的关联相反,现有文献表明普拉德-威利综合征(PWS)患者的体重减少。 研究目的:评估抗精神病药物的使用和身体质量指数(BMI) 之间的关系,住院期间BMI值有变化,滞留时间(LOS)由住院病人普拉德-威利综合征的治疗项目决定。 设计:回顾性病例

背景:患有普拉德-威利综合征(PWS)的病人发展为行为和精神疾病的风险增加,常常需要抗精神病药物(APs)治疗。在一般人群中观察到抗精神病药物与体重增加的关联相反,现有文献表明普拉德-威利综合征(PWS)患者的体重减少。

研究目的:评估抗精神病药物的使用和身体质量指数(BMI) 之间的关系,住院期间BMI值有变化,滞留时间(LOS)由住院病人普拉德-威利综合征的治疗项目决定。

设计:回顾性病例对照研究。

设置:基于医院的, 涉及儿童和成人住院病人普拉德-威利综合征治疗项目的国内外服务。

病人:病例由52名在住院期间服用抗精神病药物的普拉德-威利综合征儿科患者,97名在住院期间服用抗精神病药物的普拉德-威利综合征成人患者,和11名有抗精神病药物抵抗的随后在住院期间开始服用抗精神病药物的儿童和成人患者,所有住院期间普拉德-威利综合征抗精神病药物抵抗的患者与其年龄(岁),性别和种族划分的不同相匹配。

测量和主要结果:群体之间和群体之内身体质量指数的差异, 身体质量指数从服药期间到停药发生了变化,对病人的住院滞留时间进行分析。服药后身体质量指数较低(平均±标准差36.8±11.9公斤/米2 VS 46.7±12.5公斤/米2,p < 0.001), 儿科患者住院期间接触抗精神病药物与相匹配控制对照组相比，滞留时间增加(平均数±标准差75.9±38.5 每天 vs 57.8±23.2 每天,p = 0.005)。所有组从服药到停药(p≤0.001)身体质量指数明显降低,除了住院期间接触抗精神病药物儿科患者。抗精神病药物抵抗的患者,随后在住院期间开始服用抗精神病药物身体质量指数从服药到停药有较小的降低相对于匹配对照组(-3.011 vs -7.288公斤/米2,p=0.027)。病例组和对照组比较没有其它明显的不同。

结论:住院期间普拉德-威利综合征患者住院期间用过处方的抗精神病药物平均体重减轻,但这随患者年龄和使用抗精神病药物的时间而变。

原始出处

Elliott JP1, Cherpes G, Kamal K, Chopra I, Harrison C, Riedy M, Herk B, McCrossin M, Kalarchian M. Relationship between Antipsychotics and Weight in Patients with Prader-Willi Syndrome. Pharmacotherapy. 2015 Mar;35(3):260-8.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908188, encodeId=d93e1908188b4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jul 14 03:36:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995917, encodeId=2e68199591ec3, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 21 19:36:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738773, encodeId=b6791e3877366, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 00:36:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787170, encodeId=80b71e8717004, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Sep 17 11:36:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513053, encodeId=6c7f1513053fb, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu Apr 02 02:36:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19127, encodeId=bfa61912e77, content=好玩, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-07-14 chentianping

    #pharma#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1908188, encodeId=d93e1908188b4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jul 14 03:36:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995917, encodeId=2e68199591ec3, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 21 19:36:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738773, encodeId=b6791e3877366, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 00:36:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787170, encodeId=80b71e8717004, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Sep 17 11:36:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513053, encodeId=6c7f1513053fb, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu Apr 02 02:36:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19127, encodeId=bfa61912e77, content=好玩, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-08-21 yb6560

    #MAC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1908188, encodeId=d93e1908188b4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jul 14 03:36:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995917, encodeId=2e68199591ec3, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 21 19:36:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738773, encodeId=b6791e3877366, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 00:36:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787170, encodeId=80b71e8717004, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Sep 17 11:36:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513053, encodeId=6c7f1513053fb, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu Apr 02 02:36:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19127, encodeId=bfa61912e77, content=好玩, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-12-21 124988c7m106暂无昵称

    #ERA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1908188, encodeId=d93e1908188b4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jul 14 03:36:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995917, encodeId=2e68199591ec3, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 21 19:36:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738773, encodeId=b6791e3877366, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 00:36:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787170, encodeId=80b71e8717004, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Sep 17 11:36:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513053, encodeId=6c7f1513053fb, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu Apr 02 02:36:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19127, encodeId=bfa61912e77, content=好玩, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-09-17 jj000001

    #Pharm#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1908188, encodeId=d93e1908188b4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jul 14 03:36:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995917, encodeId=2e68199591ec3, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 21 19:36:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738773, encodeId=b6791e3877366, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 00:36:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787170, encodeId=80b71e8717004, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Sep 17 11:36:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513053, encodeId=6c7f1513053fb, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu Apr 02 02:36:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19127, encodeId=bfa61912e77, content=好玩, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-04-02 12498768m16(暂无昵称)

    #抗精神病药#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1908188, encodeId=d93e1908188b4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Jul 14 03:36:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995917, encodeId=2e68199591ec3, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 21 19:36:00 CST 2015, time=2015-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738773, encodeId=b6791e3877366, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 00:36:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787170, encodeId=80b71e8717004, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Sep 17 11:36:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513053, encodeId=6c7f1513053fb, content=<a href='/topic/show?id=bdc555596cd' target=_blank style='color:#2F92EE;'>#抗精神病药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55596, encryptionId=bdc555596cd, topicName=抗精神病药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=694d10531994, createdName=12498768m16(暂无昵称), createdTime=Thu Apr 02 02:36:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19127, encodeId=bfa61912e77, content=好玩, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c8e1619533, createdName=cd90, createdTime=Tue Mar 31 11:47:00 CST 2015, time=2015-03-31, status=1, ipAttribution=)]
    2015-03-31 cd90

    好玩

    0